Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
OBJECTIVE
To assess the outcome of patients with advanced ovarian cancer (OC) who were treated without surgery, having received upfront chemotherapy and no interval debulking surgery (IDS).


METHODS
Retrospective analysis of medical and chemotherapy records of consecutive patients with OC between 2005 and 2013 at UCL Hospitals London, UK who received neoadjuvant chemotherapy (NACT) was then found to be unsuitable for IDS following review by the multidisciplinary team.


RESULTS
Eighty-three patients (18%) out of 467 receiving NACT did not undergo IDS. Median age was 70years (range 33-88); out of these 83 patients, 43 (51.8%) presented with stage IV disease. Forty-three of these 83 patients received carboplatin and paclitaxel (CP) (51.8%) and 37 received carboplatin alone (C) (44.6%); 3 patients (3.6%) received other platinum-based combinations. Reasons for not proceeding to surgery were: poor response to chemotherapy after 3-4 cycles of NACT (61/83, 73.5%); comorbidities (12/83, 14.5%); patient decision (4/83, 4.8%). Six patients (7.2%) received <3 cycles of NACT due to a worsening clinical condition. The median overall survival (OS) for patients not undergoing IDS was 18months (95% CI 10-20months). Forty-four of 83 patients (53%) received >2 lines of chemotherapy. In a univariate analysis CP, age <70years, and absence of comorbidities were factors influencing OS. In a multivariate analysis only having received CP remained independently associated with OS (HR 0.49, 95% CI 0.29-0.84).


CONCLUSIONS
Chemotherapy alone can provide reasonable disease control in patients unsuitable for IDS and CP should be used if possible.
UCL Cancer Institute and UCL Hospitals, London, UK; Department of Gynecological and Obstetrical Sciences and Urological Sciences, University "Sapienza", Rome, Italy.
Claudia
C
Marchetti
UCL Cancer Institute and UCL Hospitals, London, UK.
Rebecca
R
Kristeleit
Cancer Division, University College Hospital, UCL Hospitals, London, UK.
Mary
M
McCormack
Department of Gynaecological Oncology, Women's Health University College Hospital, UCL Hospitals, London, UK.
Tim
T
Mould
Department of Gynaecological Oncology, Women's Health University College Hospital, UCL Hospitals, London, UK.
Adeola
A
Olaitan
Department of Gynaecological Oncology, Women's Health University College Hospital, UCL Hospitals, London, UK.
Martin
M
Widschwendter
Department of Gynaecological Oncology, Women's Health University College Hospital, UCL Hospitals, London, UK.
Nicola
N
MacDonald
UCL Cancer Institute and UCL Hospitals, London, UK. Electronic address: j.ledermann@ucl.ac.uk.
Jonathan A
JA
Ledermann
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D015897:Comorbidity; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000556:secondary*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate
D016190:Carboplatin; D017239:Paclitaxel
Advanced ovarian cancer; Carboplatin; Chemotherapy; Debulking; Neoadjuvant; Paclitaxel; Surgery